{"timestamp": "2026-01-22T18:35:45.229360", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"TP\"]},\"BIOMARKERS\":{\"AFP\":\"Unknown\",\"CA125\":\"Unknown\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.\",\"DIAGNOSIS\":{\"components\":[\"Adenocarcinoma\",\"High-grade serous carcinoma\"],\"histology\":\"High-grade serous carcinoma\",\"laterality\":\"Bilateral\",\"primary\":\"Ovarian cancer\",\"site\":\"Ovary\"},\"ECOG\":\"1\",\"GENOMICS\":{\"HRD_STATUS\":{\"method\":\"Unknown\",\"result\":\"Positive\",\"score\":\"Unknown\"},\"alterations\":[],\"testing_date\":\"Unknown\",\"testing_performed\":\"Yes\",\"testing_platform\":\"Unknown\"},\"HRD\":\"Positive\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"1\",\"cycles_planned\":\"Unknown\",\"discontinuation\":{\"detail\":\"Switched to TP chemotherapy\",\"reason\":\"Other\"},\"end_date\":\"2021-09-07\",\"in_clinical_trial\":\"No\",\"intent\":\"First_line\",\"line\":\"1L\",\"pfs_days\":\"41\",\"regimen\":\"顺铂50mg腹腔化疗\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2021-09-06\"},{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"6\",\"cycles_planned\":\"6\",\"discontinuation\":{\"detail\":\"Completed 6 cycles\",\"reason\":\"Completed\"},\"end_date\":\"2022-03-22\",\"in_clinical_trial\":\"No\",\"intent\":\"First_line\",\"line\":\"1L\",\"pfs_days\":\"Unknown\",\"regimen\":\"TP\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2021-10-18\"},{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"Unknown\",\"cycles_planned\":\"Unknown\",\"discontinuation\":{\"detail\":\"Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing\",\"reason\":\"Other\"},\"end_date\":\"Unknown\",\"in_clinical_trial\":\"No\",\"intent\":\"Maintenance\",\"line\":\"1L\",\"pfs_days\":\"Unknown\",\"regimen\":\"尼拉帕利\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2022-04-Unknown\"}],\"MAINTENANCE\":\"Yes\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Yes\",\"regimens\":[\"尼拉帕利\"],\"start_date\":\"2022-04-Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2022-03-22\",\"evidence\":\"TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.\",\"evidence_type\":\"Unknown\",\"first_relapse_date\":\"Unknown\",\"line\":\"1L\",\"start_date\":\"2021-10-18\",\"status\":\"Unknown\"}],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"No\",\"RELAPSE_DATE\":{\"date\":\"Unknown\",\"evidence\":\"No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.\",\"type\":\"Unknown\"},\"SCENE\":\"Maintenance_surveillance_followup\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2021-08-26\",\"performed\":\"Yes\",\"procedure\":\"Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2021-08-26\",\"description\":\"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy\",\"event_type\":\"Surgery\",\"key_result\":\"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08-26\",\"description\":\"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases\",\"event_type\":\"Diagnosis\",\"key_result\":\"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive\",\"regimen_or_test\":\"Pathology\"},{\"date\":\"2021-09-06\",\"description\":\"Intraperitoneal chemotherapy with cisplatin 50mg\",\"event_type\":\"Chemo\",\"key_result\":\"Completed over 2021-09-06 and 2021-09-07\",\"regimen_or_test\":\"顺铂50mg腹腔化疗\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy, planned 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Completed 6 cycles, last on 2022-03-22\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-03-22\",\"description\":\"Last cycle of TP chemotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"Adjuvant chemotherapy completed\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-04-18\",\"description\":\"Complete blood count showing thrombocytopenia\",\"event_type\":\"Lab\",\"key_result\":\"PLT:33\",\"regimen_or_test\":\"Blood routine\"},{\"date\":\"2022-04-26\",\"description\":\"Stopped niraparib due to strong adverse reactions\",\"event_type\":\"Other\",\"key_result\":\"Maintenance paused\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-05-23\",\"description\":\"Restarted niraparib 1# qd\",\"event_type\":\"Chemo\",\"key_result\":\"Maintenance resumed\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-06-24\",\"description\":\"Abdominal wall hernia repair at Zhongshan Hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Niraparib held for 3 weeks around surgery\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-09-27\",\"description\":\"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior\",\"event_type\":\"Imaging\",\"key_result\":\"No new malignant findings reported; abdominal details deferred\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-08\",\"description\":\"CT showing liver segment VII hemangioma and left renal cyst, stable\",\"event_type\":\"Imaging\",\"key_result\":\"No new findings; chest to correlate with other exams\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-25\",\"description\":\"Pelvic MRI after ovarian cancer surgery\",\"event_type\":\"Imaging\",\"key_result\":\"No abnormal soft tissue in pelvis; follow-up recommended\",\"regimen_or_test\":\"MR\"},{\"date\":\"2022-12-30\",\"description\":\"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe\",\"event_type\":\"Imaging\",\"key_result\":\"Blood count and liver/kidney function generally acceptable\",\"regimen_or_test\":\"Imaging\"},{\"date\":\"2023-01-09\",\"description\":\"Recent blood routine showed platelet count 34 (year not fully specified)\",\"event_type\":\"Lab\",\"key_result\":\"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)\",\"regimen_or_test\":\"Blood routine\"}]},\"VISIT_DATE\":\"2023-01-09\",\"first_relapse_date\":\"Unknown\",\"last_platinum_end_date\":\"2022-03-22\"},\"CLINICAL_TRIALS\":[],\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"Other\",\"history\":[{\"date\":\"2022-04-18\",\"flag\":\"↓\",\"value\":\"PLT:33\"}],\"latest\":{\"date\":\"2022-04-18\",\"flag\":\"↓\",\"value\":\"PLT:33\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"}],\"milestones\":[{\"date\":\"2021-08-26\",\"description\":\"Primary debulking surgery for ovarian cancer\",\"type\":\"Surgery\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy\",\"type\":\"ChemoStart\"},{\"date\":\"2022-03-22\",\"description\":\"Completed TP chemotherapy\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-04-18\",\"description\":\"Thrombocytopenia (PLT 33) on blood routine\",\"type\":\"Other\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing\",\"last_admin_date\":\"Unknown\",\"name\":\"尼拉帕利\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[\"HRD\"]},\"monitoring_points\":[{\"drug_or_class\":\"尼拉帕利\",\"monitoring\":[\"Monitor platelet count due to prior thrombocytopenia\"]}],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"顺铂50mg腹腔化疗\",\"TP\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"High-grade serous carcinoma\",\"Myometrial leiomyomas\",\"Chronic cervicitis\"],\"date\":\"2021-08-26\",\"diagnosis\":\"Adenocarcinoma consistent with high-grade serous carcinoma\",\"grade\":\"High-grade\",\"ihc\":[],\"involvement_sites\":[\"Left ovary\",\"Right ovary\",\"Left fallopian tube\",\"Right fallopian tube\",\"Uterine myometrium\",\"Pelvic and abdominal peritoneum\",\"Partial rectosigmoid colon from serosa to superficial muscle\",\"Omentum\",\"Left paracolic gutter peritoneum\",\"Small bowel mesentery\",\"Sigmoid mesentery\",\"Appendiceal serosa\",\"Pelvic lymph nodes\",\"Para-aortic and mesenteric lymph nodes (some positive)\"],\"laterality\":\"Bilateral ovarian involvement\",\"molecular\":[{\"result\":\"Positive\",\"test\":\"HRD\"}],\"raw_text\":\"术后病理：标本类型:扩大子宫+双附件+巨大盆块+部分直乙结肠+盆腹腔多病灶肿瘤大小:左侧：3.5×2×1.5cm；右侧：6×5.5×4.5cm肿瘤侧别:双侧病理类型:腺癌，结合免疫组化结果（I2021-07819），符合高级别浆液性癌。其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:见癌累及；肌壁间平滑肌瘤（多枚，直径0.5-2cm）盆腹腔多部位病灶:（部分直乙结肠）见癌累及，自浆膜层浸润至浅肌层，肠管两切缘未见癌累及。（大网膜、大网膜及盆腔肿块、左侧结肠旁沟腹膜、小肠系膜肿瘤、乙状结肠系膜肿瘤）见癌累及.（阑尾及周围肿块） 浆膜层见癌累及。其他:送检淋巴结（6/24）见癌转移，其中：左盆腔淋巴结（1/4）；右盆腔淋巴结（3/8）；腹主肠系膜下方淋巴结（1/4）； 肠系膜下动脉上方淋巴结（1/2）；腹主动脉旁淋巴结（0/6）。\",\"sample_type\":\"Surgical resection\",\"site\":\"Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes\",\"tumor_size\":\"Left ovary 3.5×2×1.5cm; right ovary 6×5.5×4.5cm\",\"uncertainty_or_missing\":[\"FIGO stage not provided\",\"IHC panel details not provided\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Lung\",\"Pleura\",\"Chest\"],\"date\":\"2022-09-27\",\"findings\":[\"Right upper lung arteriovenous fistula similar to prior\",\"Right upper lung apical segment small nodule similar to prior\",\"Left upper lung scattered tiny nodules\",\"Small bilateral pleural effusions decreased compared with prior\",\"Scattered chronic inflammatory and fibrotic changes in lungs\",\"Atelectasis improved\",\"Nodule at right cardiophrenic angle less apparent\"],\"impression\":\"Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved\",\"modality\":\"CT\",\"trend_vs_prior\":\"Improved\"},{\"anatomic_sites\":[\"Liver\",\"Kidney\",\"Spine\"],\"date\":\"2022-10-08\",\"findings\":[\"Hemangioma in liver right lobe segment VII similar to prior\",\"Left renal cyst similar to prior\",\"Localized uneven sclerotic change in lumbar vertebrae similar to prior\"],\"impression\":\"Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams\",\"modality\":\"CT\",\"trend_vs_prior\":\"Stable\"},{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-25\",\"findings\":[\"Postoperative changes after ovarian cancer surgery\",\"No abnormal soft tissue mass in pelvis\"],\"impression\":\"No pelvic recurrence; follow-up recommended\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Stable\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2021-08-26\",\"description\":\"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy\",\"event_type\":\"Surgery\",\"key_result\":\"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08-26\",\"description\":\"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases\",\"event_type\":\"Diagnosis\",\"key_result\":\"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive\",\"regimen_or_test\":\"Pathology\"},{\"date\":\"2021-09-06\",\"description\":\"Intraperitoneal chemotherapy with cisplatin 50mg\",\"event_type\":\"Chemo\",\"key_result\":\"Completed over 2021-09-06 and 2021-09-07\",\"regimen_or_test\":\"顺铂50mg腹腔化疗\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy, planned 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Completed 6 cycles, last on 2022-03-22\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-03-22\",\"description\":\"Last cycle of TP chemotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"Adjuvant chemotherapy completed\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-04-18\",\"description\":\"Complete blood count showing thrombocytopenia\",\"event_type\":\"Lab\",\"key_result\":\"PLT:33\",\"regimen_or_test\":\"Blood routine\"},{\"date\":\"2022-04-26\",\"description\":\"Stopped niraparib due to strong adverse reactions\",\"event_type\":\"Other\",\"key_result\":\"Maintenance paused\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-05-23\",\"description\":\"Restarted niraparib 1# qd\",\"event_type\":\"Chemo\",\"key_result\":\"Maintenance resumed\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-06-24\",\"description\":\"Abdominal wall hernia repair at Zhongshan Hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Niraparib held for 3 weeks around surgery\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-09-27\",\"description\":\"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior\",\"event_type\":\"Imaging\",\"key_result\":\"No new malignant findings reported; abdominal details deferred\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-08\",\"description\":\"CT showing liver segment VII hemangioma and left renal cyst, stable\",\"event_type\":\"Imaging\",\"key_result\":\"No new findings; chest to correlate with other exams\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-25\",\"description\":\"Pelvic MRI after ovarian cancer surgery\",\"event_type\":\"Imaging\",\"key_result\":\"No abnormal soft tissue in pelvis; follow-up recommended\",\"regimen_or_test\":\"MR\"},{\"date\":\"2022-12-30\",\"description\":\"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe\",\"event_type\":\"Imaging\",\"key_result\":\"Blood count and liver/kidney function generally acceptable\",\"regimen_or_test\":\"Imaging\"},{\"date\":\"2023-01-09\",\"description\":\"Recent blood routine showed platelet count 34 (year not fully specified)\",\"event_type\":\"Lab\",\"key_result\":\"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)\",\"regimen_or_test\":\"Blood routine\"}]},\"TOXICITIES\":[{\"attribution\":\"Probable\",\"dose_modification\":\"Yes\",\"onset_date\":\"2022-04-18\",\"outcome\":\"Resolved\",\"related_line\":\"1L\",\"related_regimen\":\"尼拉帕利\",\"severity\":\"Severe\",\"toxicity\":\"Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)\"}]}", "final_output": "Final Assessment:\nDisseminated high‑grade serous ovarian carcinoma, HRD‑positive and BRCA‑wildtype on NGS, currently in radiologic remission on first‑line PARP maintenance with acceptable blood counts, organ function, and tumor markers [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB] [@OH2201222 | Genomics]. Key uncertainties are exact FIGO stage, full pathology/IHC characterization, and optimal total duration of maintenance within the guideline‑supported 2–3‑year window [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. Updated imaging beyond 2022‑10‑25 and longitudinal marker/symptom data are still needed to confirm ongoing remission [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].\n\nCore Treatment Strategy:\n- Continue current first‑line PARP maintenance toward finite 2–3‑year duration, with regular CBC, chemistries, and toxicity review [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].  \n- Check CA125±HE4 at each follow‑up visit to establish trends and support early detection of biochemical relapse [@20230109|9701878 | LAB].  \n- Obtain contrast‑enhanced CT chest/abdomen plus pelvic MRI now to document current remission baseline for surveillance [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \n- Retrieve and finalize FIGO stage and full pathology/IHC (I2021‑07819), integrating HRD‑positive, BRCA‑wildtype NGS into the staging summary [@OH2201222 | Genomics].  \n\nChange Triggers:\n- If CA125/HE4 rise or new symptoms develop, advance imaging timing and consider FDG PET/CT for occult or equivocal disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].  \n- If CT/MR or PET/CT demonstrates recurrence, reclassify line of therapy and transition from maintenance to appropriate systemic relapse management pathway.\n\n---\n## References\n\n### Guidelines\n\n[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n  Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 8\n  Content: MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity...\n\n[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\n  Document: nccn_ovariancancer_v3_2025__v00000000, Page 15\n  Content: based chemotherapy,n\npreferred for first\nrecurrence...\n\n### Literature\n\n### Clinical Trials\n\n### Clinical Reports\n\n[@20230109|5600622 | LAB]\n  LAB ID: 20230109|5600622 | Date: 2023-01-09\n  Content: 中性粒细胞% 62.0 % (GRAN) PLT分布宽度 10 % (PDW) 嗜碱性细胞数 0.06 *10^9/L...\n\n[@20230109|8300382 | LAB]\n  LAB ID: 20230109|8300382 | Date: 2023-01-09\n  Content: γ-谷氨酰基转移酶 24 U/L (GGT) 尿素 4.65 mmol/l (UREA) 乳酸脱氢酶 267 U/L...\n\n[@20230109|9701878 | LAB]\n  LAB ID: 20230109|9701878 | Date: 2023-01-09\n  Content: 糖链抗原125 6.45 U/ml (CA125) 人附睾蛋白4 78.30 pmol/L (HE4)...\n\n[@OH2201222 | Genomics]\n  Genomics ID: OH2201222 | Date: 2022-01-24\n  Content: HRD 阳性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2...\n\n[@2022-09-27|CT | CT]\n  CT ID: 2022-09-27|CT | Date: 2022-09-27\n  Content: 对比前片2021-09-01：右上肺动脉分支远端增粗且与右上肺静脉分支相通，右上肺静脉分支增粗，同前。右肺尖段见小结节同...\n\n[@2022-09-29|CT | CT]\n  CT ID: 2022-09-29|CT | Date: 2022-09-29\n  Content: 对比2021-09-01：左下腹造瘘影，肝右叶VII段结节较前相仿，边缘结节样强化。肝内外胆管无扩张，脾、胆囊、胰腺大小...\n\n[@2022-10-25|MR | MR]\n  MR ID: 2022-10-25|MR | Date: 2022-10-25\n  Content: 对比2021-8-17：卵巢癌术后，阴道残端未见明显增厚，盆腔未见明显异常信号肿块，盆组及腹股沟淋巴结未见明显肿大，盆腔...\n", "initial_ops": {"chair": "- Continue current PARP maintenance with close platelet monitoring; counts currently normal at PLT 145 and organ function acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB].  \n\n- Maintain surveillance: periodic CA125/HE4 and cross‑sectional imaging; no pelvic recurrence on MRI 2022-10-25 [@2022-10-25|MR | MR] [@20230109|9701878 | LAB].  \n\n- First‑line PARP maintenance in HRD‑positive, post‑platinum responders is guideline‑supported; duration typically finite (2–3 years) [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].", "oncologist": "- Currently on first-line PARP-inhibitor maintenance with no radiologic recurrence; continue maintenance with close toxicity and hematologic monitoring. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Platelets and organ function now adequate for ongoing maintenance; prior thrombocytopenia has resolved. [@20230109|5600622 | LAB] [@20230109|8300382 | LAB]\n\n- Need updated cross-sectional imaging report and CA125 trend beyond 2022-10-25 to better define response and surveillance plan.", "radiologist": "- No measurable pelvic recurrence or mass; postoperative pelvis remains clear of disease on MRI. [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Chest CT shows stable small pulmonary nodules and AV fistula; prior pleural effusions and atelectasis have improved. [@2022-09-27|CT | CT]\n\n- Abdominal CT demonstrates stable benign-appearing liver hemangioma, left renal cyst, and lumbar sclerosis; no ascites or adenopathy. [@2022-09-29|CT | CT]", "pathologist": "- Diagnosis: disseminated high-grade serous carcinoma involving bilateral adnexa, uterus, bowel serosa/muscle, peritoneum, nodes; FIGO stage needs confirmation. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]\n\n- HRD positive on comprehensive NGS; no pathogenic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 variants. [@OH2201222 | Genomics]\n\n- Missing/uncertain: full original IHC panel report (I2021-07819), FIGO stage assignment, CA125 and other serum tumor markers. Unknown/needs update.", "nuclear": "- No PET/FDG study is available; metabolic staging and assessment of recurrence risk are currently impossible—PET/CT acquisition is needed.  \n\n- Prior CT and pelvic MR show no evident pelvic recurrence; PET could upstage by revealing extra-pelvic hypermetabolic disease. [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]  \n\n- In ovarian cancer, FDG PET/CT improves detection of nodal and distant metastases and suspected recurrence over morphology alone. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]"}, "merged_summary": "Key Knowledge:\n- Disseminated high-grade serous carcinoma, HRD-positive and BRCA-wildtype on NGS, on first-line PARP inhibitor maintenance after platinum response.  \n- Prior thrombocytopenia has resolved; current blood counts, organ function, and CA125/HE4 are acceptable for continued PARP maintenance.  \n- Cross-sectional imaging (CT chest/abdomen and pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing lesions (liver hemangioma, renal cyst, lumbar sclerosis, small pulmonary nodules, AV fistula).  \n- PARP maintenance in HRD-positive disease is guideline-supported and intended as finite therapy, generally over 2–3 years, with regular toxicity and hematologic monitoring.  \n- Current surveillance strategy is morphology-based (CT/MR) with serial CA125±HE4.\n\nControversies:\n- Exact optimal total duration of PARP maintenance within the 2–3-year window for this individual patient.  \n- Role and timing of FDG PET/CT in an asymptomatic patient in radiologic remission, given guidelines favor reserving PET/CT for biochemical rise or equivocal CT/MR.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819) and integrated final pathology summary including HRD/NGS findings.  \n- Updated imaging beyond 2022-10-25 to confirm ongoing remission.  \n- Longitudinal CA125/HE4 trends and any interval clinical symptoms or PARP-related toxicities.  \n- No prior FDG PET/CT; metabolic staging and assessment for occult disease remain incomplete (to be done only if triggered).\n\nWorking Plan:\n- Continue current first-line PARP inhibitor maintenance toward a finite 2–3-year duration, with close hematologic, organ-function, and toxicity monitoring.  \n- Implement structured surveillance: CA125±HE4 at each visit and updated contrast-enhanced CT chest/abdomen plus pelvic MRI now, then at guideline-consistent intervals or earlier if markers/symptoms change.  \n- Retrieve and document complete pathology/IHC report and confirm FIGO stage; integrate HRD-positive, BRCA-wildtype NGS results into the final pathology/staging summary.  \n- Reserve FDG PET/CT for rising CA125/HE4, new concerning symptoms, or equivocal/new lesions on CT/MR, to reassess nodal/peritoneal and extra-pelvic disease if triggered.", "final_round_ops": {"Round 1": {"chair": "- Continue current PARP maintenance with close hematologic/organ monitoring; counts and CA125/HE4 currently acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB].  \n\n- Implement surveillance: serial markers (CA125±HE4) and scheduled CT chest/abdomen plus pelvic MRI; obtain updated imaging beyond 2022-10-25 [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \n\n- Before altering maintenance duration, complete FIGO staging and full IHC report, and consider PET/CT only if markers rise or CT/MR equivocal [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12].", "oncologist": "- Continue first-line PARP-inhibitor maintenance toward a finite 2–3‑year total duration, with regular toxicity and blood-count monitoring. [@20230109|5600622 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Implement surveillance with CA125±HE4 every visit and CT chest/abdomen plus pelvic MRI approximately annually, or sooner if markers/symptoms change. [@20230109|9701878 | LAB] [@2022-10-25|MR | MR]\n\n- Obtain complete pathology/IHC and FIGO stage (I2021-07819); reserve FDG PET/CT for rising markers or equivocal CT/MR findings. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]", "radiologist": "- Obtain updated contrast-enhanced CT chest/abdomen and pelvic MRI now to confirm ongoing radiologic remission and guide surveillance intervals. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\n\n- If future CT/MR shows equivocal lesions or tumor markers rise, add FDG PET/CT to assess occult nodal/extra-pelvic disease. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Pending new imaging, continue morphology-based surveillance with CT/MR at guideline-consistent intervals; no current evidence of measurable recurrence radiologically. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]", "pathologist": "- Confirm and document FIGO stage plus full pathology/IHC report I2021-07819 for definitive staging and biomarker profile. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]\n\n- Ensure HRD-positive, BRCA-wildtype molecular summary from NGS (including negative BRCA1/2 and other genes) is clearly integrated into the pathology report. [@OH2201222 | Genomics]\n\n- Pathology file should explicitly correlate disseminated high-grade serous carcinoma distribution with final stage once imaging and clinical data are updated.", "nuclear": "- Reserve FDG PET/CT for rising CA125/HE4, new symptoms, or equivocal/new lesions on follow-up CT/MR. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]  \n\n- When triggered, PET/CT should specifically reassess nodal basins, peritoneum, and extra-pelvic sites to upstage or confirm remission.  \n\n- Until a trigger occurs, continue morphology-based surveillance; metabolic staging remains incomplete due to absence of prior PET/CT (unknown/needs update)."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].", "radiologist": "We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR].", "pathologist": null, "nuclear": "Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]."}, "oncologist": {"chair": "For regimen decisions, I still lack confirmed FIGO stage and full pathology/IHC (report I2021-07819), plus updated imaging and CA125 trend after 2022-10-25 and 2023-01-09 labs, which are critical to justify ongoing first-line maintenance versus later surveillance-only strategy. [@20230109|5600622 | LAB] [@20230109|9701878 | LAB]", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": "From an imaging standpoint, we lack any cross-sectional studies after 2022-10-25 to confirm continued radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]", "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": "From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]", "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Continue current PARP maintenance with close platelet monitoring; counts currently normal at PLT 145 and organ function acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB].  \n\n- Maintain surveillance: periodic CA125/HE4 and cross‑sectional imaging; no pelvic recurrence on MRI 2022-10-25 [@2022-10-25|MR | MR] [@20230109|9701878 | LAB].  \n\n- First‑line PARP maintenance in HRD‑positive, post‑platinum responders is guideline‑supported; duration typically finite (2–3 years) [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].", "timestamp": "2026-01-22T18:34:17.562119"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-09 09:23:13.113000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR].\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\",\"why\":\"missing\"}]}", "timestamp": "2026-01-22T18:34:34.585818"}, {"role": "chair", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] | pathologist->chair(missing): FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3] | nuclear->radiologist(missing): From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. | chair→radiologist: We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR]. | chair→nuclear: Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Continue current PARP maintenance with close hematologic/organ monitoring; counts and CA125/HE4 currently acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB].  \n\n- Implement surveillance: serial markers (CA125±HE4) and scheduled CT chest/abdomen plus pelvic MRI; obtain updated imaging beyond 2022-10-25 [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \n\n- Before altering maintenance duration, complete FIGO staging and full IHC report, and consider PET/CT only if markers rise or CT/MR equivocal [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12].", "timestamp": "2026-01-22T18:35:10.865686"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-09 09:23:13.113000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\n# MDT DISCUSSION SUMMARY\nKey Knowledge:\n- Disseminated high-grade serous carcinoma, HRD-positive and BRCA-wildtype on NGS, on first-line PARP inhibitor maintenance after platinum response.  \n- Prior thrombocytopenia has resolved; current blood counts, organ function, and CA125/HE4 are acceptable for continued PARP maintenance.  \n- Cross-sectional imaging (CT chest/abdomen and pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing lesions (liver hemangioma, renal cyst, lumbar sclerosis, small pulmonary nodules, AV fistula).  \n- PARP maintenance in HRD-positive disease is guideline-supported and intended as finite therapy, generally over 2–3 years, with regular toxicity and hematologic monitoring.  \n- Current surveillance strategy is morphology-based (CT/MR) with serial CA125±HE4.\n\nControversies:\n- Exact optimal total duration of PARP maintenance within the 2–3-year window for this individual patient.  \n- Role and timing of FDG PET/CT in an asymptomatic patient in radiologic remission, given guidelines favor reserving PET/CT for biochemical rise or equivocal CT/MR.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819) and integrated final pathology summary including HRD/NGS findings.  \n- Updated imaging beyond 2022-10-25 to confirm ongoing remission.  \n- Longitudinal CA125/HE4 trends and any interval clinical symptoms or PARP-related toxicities.  \n- No prior FDG PET/CT; metabolic staging and assessment for occult disease remain incomplete (to be done only if triggered).\n\nWorking Plan:\n- Continue current first-line PARP inhibitor maintenance toward a finite 2–3-year duration, with close hematologic, organ-function, and toxicity monitoring.  \n- Implement structured surveillance: CA125±HE4 at each visit and updated contrast-enhanced CT chest/abdomen plus pelvic MRI now, then at guideline-consistent intervals or earlier if markers/symptoms change.  \n- Retrieve and document complete pathology/IHC report and confirm FIGO stage; integrate HRD-positive, BRCA-wildtype NGS results into the final pathology/staging summary.  \n- Reserve FDG PET/CT for rising CA125/HE4, new concerning symptoms, or equivocal/new lesions on CT/MR, to reassess nodal/peritoneal and extra-pelvic disease if triggered.\n\n# INITIAL EXPERT OPINIONS\n- chair: - Continue current PARP maintenance with close platelet monitoring; counts currently normal at PLT 145 and organ function acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB].  \n\n- Maintain \n- oncologist: - Currently on first-line PARP-inhibitor maintenance with no radiologic recurrence; continue maintenance with close toxicity and hematologic monitoring. [@guideline:esmo_cpg_epithelialovarian_2023__v0\n- radiologist: - No measurable pelvic recurrence or mass; postoperative pelvis remains clear of disease on MRI. [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Chest CT show\n- pathologist: - Diagnosis: disseminated high-grade serous carcinoma involving bilateral adnexa, uterus, bowel serosa/muscle, peritoneum, nodes; FIGO stage needs confirmation. [@guideline:esmo_cpg_epithelialovarian_\n- nuclear: - No PET/FDG study is available; metabolic staging and assessment of recurrence risk are currently impossible—PET/CT acquisition is needed.  \n\n- Prior CT and pelvic MR show no evident pelvic recurrenc\n\n# DISCUSSION INTERACTIONS\nRound 1: R1T1: chair→oncologist: Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, f | R1T1: chair→radiologist: We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging aft | R1T1: chair→nuclear: Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear  | R1T1: oncologist→chair: For regimen decisions, I still lack confirmed FIGO stage and full pathology/IHC (report I2021-07819) | R1T1: radiologist→oncologist: From an imaging standpoint, we lack any cross-sectional studies after 2022-10-25 to confirm continue\n\n\n\n# FINAL REFINED PLANS (All experts, all rounds)\n{\n  \"Round 1\": {\n    \"chair\": \"- Continue current PARP maintenance with close hematologic/organ monitoring; counts and CA125/HE4 currently acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB].  \\n\\n- Implement surveillance: serial markers (CA125±HE4) and scheduled CT chest/abdomen plus pelvic MRI; obtain updated imaging beyond 2022-10-25 [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \\n\\n- Before altering maintenance duration, complete FIGO staging and full IHC report, and consider PET/CT only if markers rise or CT/MR equivocal [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12].\",\n    \"oncologist\": \"- Continue first-line PARP-inhibitor maintenance toward a finite 2–3‑year total duration, with regular toxicity and blood-count monitoring. [@20230109|5600622 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\\n\\n- Implement surveillance with CA125±HE4 every visit and CT chest/abdomen plus pelvic MRI approximately annually, or sooner if markers/symptoms change. [@20230109|9701878 | LAB] [@2022-10-25|MR | MR]\\n\\n- Obtain complete pathology/IHC and FIGO stage (I2021-07819); reserve FDG PET/CT for rising markers or equivocal CT/MR findings. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\",\n    \"radiologist\": \"- Obtain updated contrast-enhanced CT chest/abdomen and pelvic MRI now to confirm ongoing radiologic remission and guide surveillance intervals. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\\n\\n- If future CT/MR shows equivocal lesions or tumor markers rise, add FDG PET/CT to assess occult nodal/extra-pelvic disease. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\\n\\n- Pending new imaging, continue morphology-based surveillance with CT/MR at guideline-consistent intervals; no current evidence of measurable recurrence radiologically. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\",\n    \"pathologist\": \"- Confirm and document FIGO stage plus full pathology/IHC report I2021-07819 for definitive staging and biomarker profile. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]\\n\\n- Ensure HRD-positive, BRCA-wildtype molecular summary from NGS (including negative BRCA1/2 and other genes) is clearly integrated into the pathology report. [@OH2201222 | Genomics]\\n\\n- Pathology file should explicitly correlate disseminated high-grade serous carcinoma distribution with final stage once imaging and clinical data are updated.\",\n    \"nuclear\": \"- Reserve FDG PET/CT for rising CA125/HE4, new symptoms, or equivocal/new lesions on follow-up CT/MR. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]  \\n\\n- When triggered, PET/CT should specifically reassess nodal basins, peritoneum, and extra-pelvic sites to upstage or confirm remission.  \\n\\n- Until a trigger occurs, continue morphology-based surveillance; metabolic staging remains incomplete due to absence of prior PET/CT (unknown/needs update).\"\n  }\n}\n\n# CLINICAL TRIAL RECOMMENDATION (from assistant)\nTrial Recommendation:\n- id: None\n- name: None\n- Reason: Disease setting/line and required biomarkers for available trials are not clearly met based on the case.\n- Missing eligibility confirmations (0-2 items):\n  - HER2 / TF / EGFR/HER3 / HPV16 status and other trial-specific biomarkers\n  - Clear documentation of recurrent/metastatic or unresectable disease and prior systemic therapy lines in the advanced setting\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@OH2203828|2022-04-18 | Genomics], [@2022-12-29 | MR], [@2022-12-29 | CT]). Note: Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If a clinical trial has been recommended by the assistant and you judge it appropriate for the patient, mention it naturally within Core Treatment Strategy or Change Triggers and cite it using [@trial | trial_id] format (e.g., [@trial | 350]).\n- If experts disagree, pick the safest plan and state the key uncertainty.\n- You MUST consider the MDT discussion summary and interactions above when making your decision.\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words \"if X, then adjust management from A to B\" >\n- < ≤20 words \"if X, then adjust management from A to B\" >\n", "assistant_reply": "Final Assessment:\nDisseminated high‑grade serous ovarian carcinoma, HRD‑positive and BRCA‑wildtype on NGS, currently in radiologic remission on first‑line PARP maintenance with acceptable blood counts, organ function, and tumor markers [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB] [@OH2201222 | Genomics]. Key uncertainties are exact FIGO stage, full pathology/IHC characterization, and optimal total duration of maintenance within the guideline‑supported 2–3‑year window [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. Updated imaging beyond 2022‑10‑25 and longitudinal marker/symptom data are still needed to confirm ongoing remission [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].\n\nCore Treatment Strategy:\n- Continue current first‑line PARP maintenance toward finite 2–3‑year duration, with regular CBC, chemistries, and toxicity review [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].  \n- Check CA125±HE4 at each follow‑up visit to establish trends and support early detection of biochemical relapse [@20230109|9701878 | LAB].  \n- Obtain contrast‑enhanced CT chest/abdomen plus pelvic MRI now to document current remission baseline for surveillance [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \n- Retrieve and finalize FIGO stage and full pathology/IHC (I2021‑07819), integrating HRD‑positive, BRCA‑wildtype NGS into the staging summary [@OH2201222 | Genomics].  \n\nChange Triggers:\n- If CA125/HE4 rise or new symptoms develop, advance imaging timing and consider FDG PET/CT for occult or equivocal disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].  \n- If CT/MR or PET/CT demonstrates recurrence, reclassify line of therapy and transition from maintenance to appropriate systemic relapse management pathway.", "timestamp": "2026-01-22T18:35:45.224019"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Currently on first-line PARP-inhibitor maintenance with no radiologic recurrence; continue maintenance with close toxicity and hematologic monitoring. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Platelets and organ function now adequate for ongoing maintenance; prior thrombocytopenia has resolved. [@20230109|5600622 | LAB] [@20230109|8300382 | LAB]\n\n- Need updated cross-sectional imaging report and CA125 trend beyond 2022-10-25 to better define response and surveillance plan.", "timestamp": "2026-01-22T18:34:19.914101"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-09 09:23:13.113000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"For regimen decisions, I still lack confirmed FIGO stage and full pathology/IHC (report I2021-07819), plus updated imaging and CA125 trend after 2022-10-25 and 2023-01-09 labs, which are critical to justify ongoing first-line maintenance versus later surveillance-only strategy. [@20230109|5600622 | LAB] [@20230109|9701878 | LAB]\",\"why\":\"missing\"}]}", "timestamp": "2026-01-22T18:34:36.570945"}, {"role": "oncologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] | pathologist->chair(missing): FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3] | nuclear->radiologist(missing): From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. | chair→radiologist: We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR]. | chair→nuclear: Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Continue first-line PARP-inhibitor maintenance toward a finite 2–3‑year total duration, with regular toxicity and blood-count monitoring. [@20230109|5600622 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Implement surveillance with CA125±HE4 every visit and CT chest/abdomen plus pelvic MRI approximately annually, or sooner if markers/symptoms change. [@20230109|9701878 | LAB] [@2022-10-25|MR | MR]\n\n- Obtain complete pathology/IHC and FIGO stage (I2021-07819); reserve FDG PET/CT for rising markers or equivocal CT/MR findings. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]", "timestamp": "2026-01-22T18:35:20.603478"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- No measurable pelvic recurrence or mass; postoperative pelvis remains clear of disease on MRI. [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Chest CT shows stable small pulmonary nodules and AV fistula; prior pleural effusions and atelectasis have improved. [@2022-09-27|CT | CT]\n\n- Abdominal CT demonstrates stable benign-appearing liver hemangioma, left renal cyst, and lumbar sclerosis; no ascites or adenopathy. [@2022-09-29|CT | CT]", "timestamp": "2026-01-22T18:34:21.729431"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-09 09:23:13.113000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"From an imaging standpoint, we lack any cross-sectional studies after 2022-10-25 to confirm continued radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\",\"why\":\"missing\"}]}", "timestamp": "2026-01-22T18:34:38.448119"}, {"role": "radiologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] | pathologist->chair(missing): FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3] | nuclear->radiologist(missing): From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. | chair→radiologist: We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR]. | chair→nuclear: Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Obtain updated contrast-enhanced CT chest/abdomen and pelvic MRI now to confirm ongoing radiologic remission and guide surveillance intervals. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\n\n- If future CT/MR shows equivocal lesions or tumor markers rise, add FDG PET/CT to assess occult nodal/extra-pelvic disease. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Pending new imaging, continue morphology-based surveillance with CT/MR at guideline-consistent intervals; no current evidence of measurable recurrence radiologically. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]", "timestamp": "2026-01-22T18:35:24.238112"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- Diagnosis: disseminated high-grade serous carcinoma involving bilateral adnexa, uterus, bowel serosa/muscle, peritoneum, nodes; FIGO stage needs confirmation. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]\n\n- HRD positive on comprehensive NGS; no pathogenic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 variants. [@OH2201222 | Genomics]\n\n- Missing/uncertain: full original IHC panel report (I2021-07819), FIGO stage assignment, CA125 and other serum tumor markers. Unknown/needs update.", "timestamp": "2026-01-22T18:34:23.840259"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-09 09:23:13.113000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]\",\"why\":\"missing\"}]}", "timestamp": "2026-01-22T18:34:40.102942"}, {"role": "pathologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] | pathologist->chair(missing): FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3] | nuclear->radiologist(missing): From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. | chair→radiologist: We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR]. | chair→nuclear: Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Confirm and document FIGO stage plus full pathology/IHC report I2021-07819 for definitive staging and biomarker profile. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]\n\n- Ensure HRD-positive, BRCA-wildtype molecular summary from NGS (including negative BRCA1/2 and other genes) is clearly integrated into the pathology report. [@OH2201222 | Genomics]\n\n- Pathology file should explicitly correlate disseminated high-grade serous carcinoma distribution with final stage once imaging and clinical data are updated.", "timestamp": "2026-01-22T18:35:26.239781"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nFor clinical reports, use actual report_id from report data with type: [@actual_report_id | LAB], [@actual_report_id | Genomics], [@actual_report_id | MR], [@actual_report_id | CT] (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy].", "assistant_reply": "- No PET/FDG study is available; metabolic staging and assessment of recurrence risk are currently impossible—PET/CT acquisition is needed.  \n\n- Prior CT and pelvic MR show no evident pelvic recurrence; PET could upstage by revealing extra-pelvic hypermetabolic disease. [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]  \n\n- In ovarian cancer, FDG PET/CT improves detection of nodal and distant metastases and suspected recurrence over morphology alone. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]", "timestamp": "2026-01-22T18:34:25.931512"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-09 09:23:13.113000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\n\nEVIDENCE TAGS (if your message references evidence):\n- Any factual statement about past tests/treatments must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\n- If you cite guideline/PubMed evidence or reference clinical trials, include appropriate tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\n\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences with evidence tags if applicable>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"radiologist\",\"message\":\"From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\",\"why\":\"missing\"}]}", "timestamp": "2026-01-22T18:34:42.100750"}, {"role": "nuclear", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] | pathologist->chair(missing): FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3] | nuclear->radiologist(missing): From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\nDISCUSSION HISTORY (this round):\nTurn 1: chair→oncologist: Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. | chair→radiologist: We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR]. | chair→nuclear: Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@actual_report_id | LAB/Genomics/MR/CT] using actual report_id from report data (e.g., [@20220407|17300673 | LAB], [@2022-12-29 | MR], [@2022-12-29 | CT]). Always use spaces around | for consistency: [@xxx | yyy]. or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id | Page xx] or [@pubmed | PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id | Page xx], [@pubmed | PMID], or [@trial | id].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Reserve FDG PET/CT for rising CA125/HE4, new symptoms, or equivocal/new lesions on follow-up CT/MR. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]  \n\n- When triggered, PET/CT should specifically reassess nodal basins, peritoneum, and extra-pelvic sites to upstage or confirm remission.  \n\n- Until a trigger occurs, continue morphology-based surveillance; metabolic staging remains incomplete due to absence of prior PET/CT (unknown/needs update).", "timestamp": "2026-01-22T18:35:28.172613"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Continue current PARP maintenance with close platelet monitoring; counts currently normal at PLT 145 and organ function acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB].  \\n\\n- Maintain surveillance: periodic CA125/HE4 and cross‑sectional imaging; no pelvic recurrence on MRI 2022-10-25 [@2022-10-25|MR | MR] [@20230109|9701878 | LAB].  \\n\\n- First‑line PARP maintenance in HRD‑positive, post‑platinum responders is guideline‑supported; duration typically finite (2–3 years) [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].\",\"oncologist\":\"- Currently on first-line PARP-inhibitor maintenance with no radiologic recurrence; continue maintenance with close toxicity and hematologic monitoring. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\\n\\n- Platelets and organ function now adequate for ongoing maintenance; prior thrombocytopenia has resolved. [@20230109|5600622 | LAB] [@20230109|8300382 | LAB]\\n\\n- Need updated cross-sectional imaging report and CA125 trend beyond 2022-10-25 to better define response and surveillance plan.\",\"radiologist\":\"- No measurable pelvic recurrence or mass; postoperative pelvis remains clear of disease on MRI. [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\\n\\n- Chest CT shows stable small pulmonary nodules and AV fistula; prior pleural effusions and atelectasis have improved. [@2022-09-27|CT | CT]\\n\\n- Abdominal CT demonstrates stable benign-appearing liver hemangioma, left renal cyst, and lumbar sclerosis; no ascites or adenopathy. [@2022-09-29|CT | CT]\",\"pathologist\":\"- Diagnosis: disseminated high-grade serous carcinoma involving bilateral adnexa, uterus, bowel serosa/muscle, peritoneum, nodes; FIGO stage needs confirmation. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]\\n\\n- HRD positive on comprehensive NGS; no pathogenic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 variants. [@OH2201222 | Genomics]\\n\\n- Missing/uncertain: full original IHC panel report (I2021-07819), FIGO stage assignment, CA125 and other serum tumor markers. Unknown/needs update.\",\"nuclear\":\"- No PET/FDG study is available; metabolic staging and assessment of recurrence risk are currently impossible—PET/CT acquisition is needed.  \\n\\n- Prior CT and pelvic MR show no evident pelvic recurrence; PET could upstage by revealing extra-pelvic hypermetabolic disease. [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]  \\n\\n- In ovarian cancer, FDG PET/CT improves detection of nodal and distant metastases and suspected recurrence over morphology alone. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.", "timestamp": "2026-01-22T18:34:30.633684"}, {"role": "assistant", "user_message": "You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.\n\nCURRENT_MDT_GLOBAL_KNOWLEDGE:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- High-grade serous carcinoma with disseminated involvement; HRD-positive, BRCA-wildtype on NGS.  \n- Currently in first-line PARP inhibitor maintenance after platinum response; prior thrombocytopenia resolved, platelets and organ function now adequate.  \n- Cross-sectional imaging (CT chest/abdomen, pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing findings (liver hemangioma, renal cyst, lumbar sclerosis, small lung nodules, AV fistula).  \n- PARP maintenance for HRD-positive disease is guideline-supported, typically for a finite duration (≈2–3 years).\n\nControversies:\n- Optimal duration of ongoing PARP maintenance (beyond general 2–3 year guidance) in this specific patient.  \n- Need and timing for PET/CT versus continued CT/MRI-based surveillance in an asymptomatic patient without clear radiologic recurrence.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819).  \n- Updated CA125 (and HE4 if used) trend and imaging beyond 2022-10-25.  \n- Any interval clinical symptoms or toxicities on current PARP therapy.  \n- No PET/FDG imaging to date; metabolic staging and occult disease assessment lacking.\n\nWorking Plan:\n- Continue current PARP maintenance with close hematologic/toxicity monitoring; platelets currently adequate.  \n- Maintain surveillance with serial tumor markers (CA125 ± HE4) and periodic cross-sectional imaging; obtain updated scans and marker trends.  \n- Clarify FIGO stage and complete pathology/IHC documentation in the record.  \n- Consider FDG PET/CT to refine staging and exclude occult extra-pelvic disease, especially if tumor markers rise or imaging becomes equivocal.\n\nROUND_1_FINAL_PLANS_JSON:\n{\"chair\":\"- Continue current PARP maintenance with close hematologic/organ monitoring; counts and CA125/HE4 currently acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB].  \\n\\n- Implement surveillance: serial markers (CA125±HE4) and scheduled CT chest/abdomen plus pelvic MRI; obtain updated imaging beyond 2022-10-25 [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \\n\\n- Before altering maintenance duration, complete FIGO staging and full IHC report, and consider PET/CT only if markers rise or CT/MR equivocal [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12].\",\"oncologist\":\"- Continue first-line PARP-inhibitor maintenance toward a finite 2–3‑year total duration, with regular toxicity and blood-count monitoring. [@20230109|5600622 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\\n\\n- Implement surveillance with CA125±HE4 every visit and CT chest/abdomen plus pelvic MRI approximately annually, or sooner if markers/symptoms change. [@20230109|9701878 | LAB] [@2022-10-25|MR | MR]\\n\\n- Obtain complete pathology/IHC and FIGO stage (I2021-07819); reserve FDG PET/CT for rising markers or equivocal CT/MR findings. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\",\"radiologist\":\"- Obtain updated contrast-enhanced CT chest/abdomen and pelvic MRI now to confirm ongoing radiologic remission and guide surveillance intervals. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\\n\\n- If future CT/MR shows equivocal lesions or tumor markers rise, add FDG PET/CT to assess occult nodal/extra-pelvic disease. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\\n\\n- Pending new imaging, continue morphology-based surveillance with CT/MR at guideline-consistent intervals; no current evidence of measurable recurrence radiologically. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\",\"pathologist\":\"- Confirm and document FIGO stage plus full pathology/IHC report I2021-07819 for definitive staging and biomarker profile. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]\\n\\n- Ensure HRD-positive, BRCA-wildtype molecular summary from NGS (including negative BRCA1/2 and other genes) is clearly integrated into the pathology report. [@OH2201222 | Genomics]\\n\\n- Pathology file should explicitly correlate disseminated high-grade serous carcinoma distribution with final stage once imaging and clinical data are updated.\",\"nuclear\":\"- Reserve FDG PET/CT for rising CA125/HE4, new symptoms, or equivocal/new lesions on follow-up CT/MR. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]  \\n\\n- When triggered, PET/CT should specifically reassess nodal basins, peritoneum, and extra-pelvic sites to upstage or confirm remission.  \\n\\n- Until a trigger occurs, continue morphology-based surveillance; metabolic staging remains incomplete due to absence of prior PET/CT (unknown/needs update).\"}", "assistant_reply": "Key Knowledge:\n- Disseminated high-grade serous carcinoma, HRD-positive and BRCA-wildtype on NGS, on first-line PARP inhibitor maintenance after platinum response.  \n- Prior thrombocytopenia has resolved; current blood counts, organ function, and CA125/HE4 are acceptable for continued PARP maintenance.  \n- Cross-sectional imaging (CT chest/abdomen and pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing lesions (liver hemangioma, renal cyst, lumbar sclerosis, small pulmonary nodules, AV fistula).  \n- PARP maintenance in HRD-positive disease is guideline-supported and intended as finite therapy, generally over 2–3 years, with regular toxicity and hematologic monitoring.  \n- Current surveillance strategy is morphology-based (CT/MR) with serial CA125±HE4.\n\nControversies:\n- Exact optimal total duration of PARP maintenance within the 2–3-year window for this individual patient.  \n- Role and timing of FDG PET/CT in an asymptomatic patient in radiologic remission, given guidelines favor reserving PET/CT for biochemical rise or equivocal CT/MR.\n\nMissing Info:\n- Confirmed FIGO stage at diagnosis.  \n- Full original pathology/IHC report (I2021-07819) and integrated final pathology summary including HRD/NGS findings.  \n- Updated imaging beyond 2022-10-25 to confirm ongoing remission.  \n- Longitudinal CA125/HE4 trends and any interval clinical symptoms or PARP-related toxicities.  \n- No prior FDG PET/CT; metabolic staging and assessment for occult disease remain incomplete (to be done only if triggered).\n\nWorking Plan:\n- Continue current first-line PARP inhibitor maintenance toward a finite 2–3-year duration, with close hematologic, organ-function, and toxicity monitoring.  \n- Implement structured surveillance: CA125±HE4 at each visit and updated contrast-enhanced CT chest/abdomen plus pelvic MRI now, then at guideline-consistent intervals or earlier if markers/symptoms change.  \n- Retrieve and document complete pathology/IHC report and confirm FIGO stage; integrate HRD-positive, BRCA-wildtype NGS results into the final pathology/staging summary.  \n- Reserve FDG PET/CT for rising CA125/HE4, new concerning symptoms, or equivocal/new lesions on CT/MR, to reassess nodal/peritoneal and extra-pelvic disease if triggered.", "timestamp": "2026-01-22T18:35:37.306993"}], "trial_selector": [{"role": "trial_selector", "user_message": "You are an MDT assistant for gynecologic oncology clinical trial matching.\n\nCRITICAL BEHAVIOR:\n- You MUST NOT ask the user any questions.\n- You MUST NOT request additional information.\n- You MUST NOT output anything except the required template.\n- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.\n- If eligibility is unclear due to missing key facts, you MUST output None.\n\nPATIENT CASE (facts only; do not infer):\n# ORIGINAL CASE JSON\n{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6\",\"given\":\"Yes\",\"regimens\":[\"TP\"]},\"BIOMARKERS\":{\"AFP\":\"Unknown\",\"CA125\":\"Unknown\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.\",\"DIAGNOSIS\":{\"components\":[\"Adenocarcinoma\",\"High-grade serous carcinoma\"],\"histology\":\"High-grade serous carcinoma\",\"laterality\":\"Bilateral\",\"primary\":\"Ovarian cancer\",\"site\":\"Ovary\"},\"ECOG\":\"1\",\"GENOMICS\":{\"HRD_STATUS\":{\"method\":\"Unknown\",\"result\":\"Positive\",\"score\":\"Unknown\"},\"alterations\":[],\"testing_date\":\"Unknown\",\"testing_performed\":\"Yes\",\"testing_platform\":\"Unknown\"},\"HRD\":\"Positive\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"1\",\"cycles_planned\":\"Unknown\",\"discontinuation\":{\"detail\":\"Switched to TP chemotherapy\",\"reason\":\"Other\"},\"end_date\":\"2021-09-07\",\"in_clinical_trial\":\"No\",\"intent\":\"First_line\",\"line\":\"1L\",\"pfs_days\":\"41\",\"regimen\":\"顺铂50mg腹腔化疗\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2021-09-06\"},{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"6\",\"cycles_planned\":\"6\",\"discontinuation\":{\"detail\":\"Completed 6 cycles\",\"reason\":\"Completed\"},\"end_date\":\"2022-03-22\",\"in_clinical_trial\":\"No\",\"intent\":\"First_line\",\"line\":\"1L\",\"pfs_days\":\"Unknown\",\"regimen\":\"TP\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2021-10-18\"},{\"concurrent_bevacizumab\":\"No\",\"cycles_completed\":\"Unknown\",\"cycles_planned\":\"Unknown\",\"discontinuation\":{\"detail\":\"Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing\",\"reason\":\"Other\"},\"end_date\":\"Unknown\",\"in_clinical_trial\":\"No\",\"intent\":\"Maintenance\",\"line\":\"1L\",\"pfs_days\":\"Unknown\",\"regimen\":\"尼拉帕利\",\"response_assessment\":{\"best_response\":\"Unknown\",\"ca125_response\":\"Unknown\",\"response_criteria\":\"Unknown\",\"response_date\":\"Unknown\"},\"start_date\":\"2022-04-Unknown\"}],\"MAINTENANCE\":\"Yes\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Yes\",\"regimens\":[\"尼拉帕利\"],\"start_date\":\"2022-04-Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2022-03-22\",\"evidence\":\"TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.\",\"evidence_type\":\"Unknown\",\"first_relapse_date\":\"Unknown\",\"line\":\"1L\",\"start_date\":\"2021-10-18\",\"status\":\"Unknown\"}],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"No\",\"RELAPSE_DATE\":{\"date\":\"Unknown\",\"evidence\":\"No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.\",\"type\":\"Unknown\"},\"SCENE\":\"Maintenance_surveillance_followup\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2021-08-26\",\"performed\":\"Yes\",\"procedure\":\"Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2021-08-26\",\"description\":\"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy\",\"event_type\":\"Surgery\",\"key_result\":\"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08-26\",\"description\":\"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases\",\"event_type\":\"Diagnosis\",\"key_result\":\"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive\",\"regimen_or_test\":\"Pathology\"},{\"date\":\"2021-09-06\",\"description\":\"Intraperitoneal chemotherapy with cisplatin 50mg\",\"event_type\":\"Chemo\",\"key_result\":\"Completed over 2021-09-06 and 2021-09-07\",\"regimen_or_test\":\"顺铂50mg腹腔化疗\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy, planned 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Completed 6 cycles, last on 2022-03-22\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-03-22\",\"description\":\"Last cycle of TP chemotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"Adjuvant chemotherapy completed\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-04-18\",\"description\":\"Complete blood count showing thrombocytopenia\",\"event_type\":\"Lab\",\"key_result\":\"PLT:33\",\"regimen_or_test\":\"Blood routine\"},{\"date\":\"2022-04-26\",\"description\":\"Stopped niraparib due to strong adverse reactions\",\"event_type\":\"Other\",\"key_result\":\"Maintenance paused\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-05-23\",\"description\":\"Restarted niraparib 1# qd\",\"event_type\":\"Chemo\",\"key_result\":\"Maintenance resumed\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-06-24\",\"description\":\"Abdominal wall hernia repair at Zhongshan Hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Niraparib held for 3 weeks around surgery\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-09-27\",\"description\":\"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior\",\"event_type\":\"Imaging\",\"key_result\":\"No new malignant findings reported; abdominal details deferred\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-08\",\"description\":\"CT showing liver segment VII hemangioma and left renal cyst, stable\",\"event_type\":\"Imaging\",\"key_result\":\"No new findings; chest to correlate with other exams\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-25\",\"description\":\"Pelvic MRI after ovarian cancer surgery\",\"event_type\":\"Imaging\",\"key_result\":\"No abnormal soft tissue in pelvis; follow-up recommended\",\"regimen_or_test\":\"MR\"},{\"date\":\"2022-12-30\",\"description\":\"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe\",\"event_type\":\"Imaging\",\"key_result\":\"Blood count and liver/kidney function generally acceptable\",\"regimen_or_test\":\"Imaging\"},{\"date\":\"2023-01-09\",\"description\":\"Recent blood routine showed platelet count 34 (year not fully specified)\",\"event_type\":\"Lab\",\"key_result\":\"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)\",\"regimen_or_test\":\"Blood routine\"}]},\"VISIT_DATE\":\"2023-01-09\",\"first_relapse_date\":\"Unknown\",\"last_platinum_end_date\":\"2022-03-22\"},\"CLINICAL_TRIALS\":[],\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"Other\",\"history\":[{\"date\":\"2022-04-18\",\"flag\":\"↓\",\"value\":\"PLT:33\"}],\"latest\":{\"date\":\"2022-04-18\",\"flag\":\"↓\",\"value\":\"PLT:33\"},\"reference_range\":\"Unknown\",\"unit\":\"Unknown\"}],\"milestones\":[{\"date\":\"2021-08-26\",\"description\":\"Primary debulking surgery for ovarian cancer\",\"type\":\"Surgery\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy\",\"type\":\"ChemoStart\"},{\"date\":\"2022-03-22\",\"description\":\"Completed TP chemotherapy\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-04-18\",\"description\":\"Thrombocytopenia (PLT 33) on blood routine\",\"type\":\"Other\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing\",\"last_admin_date\":\"Unknown\",\"name\":\"尼拉帕利\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[\"HRD\"]},\"monitoring_points\":[{\"drug_or_class\":\"尼拉帕利\",\"monitoring\":[\"Monitor platelet count due to prior thrombocytopenia\"]}],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"顺铂50mg腹腔化疗\",\"TP\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"High-grade serous carcinoma\",\"Myometrial leiomyomas\",\"Chronic cervicitis\"],\"date\":\"2021-08-26\",\"diagnosis\":\"Adenocarcinoma consistent with high-grade serous carcinoma\",\"grade\":\"High-grade\",\"ihc\":[],\"involvement_sites\":[\"Left ovary\",\"Right ovary\",\"Left fallopian tube\",\"Right fallopian tube\",\"Uterine myometrium\",\"Pelvic and abdominal peritoneum\",\"Partial rectosigmoid colon from serosa to superficial muscle\",\"Omentum\",\"Left paracolic gutter peritoneum\",\"Small bowel mesentery\",\"Sigmoid mesentery\",\"Appendiceal serosa\",\"Pelvic lymph nodes\",\"Para-aortic and mesenteric lymph nodes (some positive)\"],\"laterality\":\"Bilateral ovarian involvement\",\"molecular\":[{\"result\":\"Positive\",\"test\":\"HRD\"}],\"raw_text\":\"术后病理：标本类型:扩大子宫+双附件+巨大盆块+部分直乙结肠+盆腹腔多病灶肿瘤大小:左侧：3.5×2×1.5cm；右侧：6×5.5×4.5cm肿瘤侧别:双侧病理类型:腺癌，结合免疫组化结果（I2021-07819），符合高级别浆液性癌。其他部位情况:左输卵管:见癌累及右输卵管:见癌累及子宫内膜:萎缩改变宫颈:慢性炎子宫肌层:见癌累及；肌壁间平滑肌瘤（多枚，直径0.5-2cm）盆腹腔多部位病灶:（部分直乙结肠）见癌累及，自浆膜层浸润至浅肌层，肠管两切缘未见癌累及。（大网膜、大网膜及盆腔肿块、左侧结肠旁沟腹膜、小肠系膜肿瘤、乙状结肠系膜肿瘤）见癌累及.（阑尾及周围肿块） 浆膜层见癌累及。其他:送检淋巴结（6/24）见癌转移，其中：左盆腔淋巴结（1/4）；右盆腔淋巴结（3/8）；腹主肠系膜下方淋巴结（1/4）； 肠系膜下动脉上方淋巴结（1/2）；腹主动脉旁淋巴结（0/6）。\",\"sample_type\":\"Surgical resection\",\"site\":\"Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes\",\"tumor_size\":\"Left ovary 3.5×2×1.5cm; right ovary 6×5.5×4.5cm\",\"uncertainty_or_missing\":[\"FIGO stage not provided\",\"IHC panel details not provided\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Lung\",\"Pleura\",\"Chest\"],\"date\":\"2022-09-27\",\"findings\":[\"Right upper lung arteriovenous fistula similar to prior\",\"Right upper lung apical segment small nodule similar to prior\",\"Left upper lung scattered tiny nodules\",\"Small bilateral pleural effusions decreased compared with prior\",\"Scattered chronic inflammatory and fibrotic changes in lungs\",\"Atelectasis improved\",\"Nodule at right cardiophrenic angle less apparent\"],\"impression\":\"Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved\",\"modality\":\"CT\",\"trend_vs_prior\":\"Improved\"},{\"anatomic_sites\":[\"Liver\",\"Kidney\",\"Spine\"],\"date\":\"2022-10-08\",\"findings\":[\"Hemangioma in liver right lobe segment VII similar to prior\",\"Left renal cyst similar to prior\",\"Localized uneven sclerotic change in lumbar vertebrae similar to prior\"],\"impression\":\"Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams\",\"modality\":\"CT\",\"trend_vs_prior\":\"Stable\"},{\"anatomic_sites\":[\"Pelvis\"],\"date\":\"2022-10-25\",\"findings\":[\"Postoperative changes after ovarian cancer surgery\",\"No abnormal soft tissue mass in pelvis\"],\"impression\":\"No pelvic recurrence; follow-up recommended\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Stable\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2021-08-26\",\"description\":\"Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy\",\"event_type\":\"Surgery\",\"key_result\":\"Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2021-08-26\",\"description\":\"Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases\",\"event_type\":\"Diagnosis\",\"key_result\":\"High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive\",\"regimen_or_test\":\"Pathology\"},{\"date\":\"2021-09-06\",\"description\":\"Intraperitoneal chemotherapy with cisplatin 50mg\",\"event_type\":\"Chemo\",\"key_result\":\"Completed over 2021-09-06 and 2021-09-07\",\"regimen_or_test\":\"顺铂50mg腹腔化疗\"},{\"date\":\"2021-10-18\",\"description\":\"Started TP chemotherapy, planned 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Completed 6 cycles, last on 2022-03-22\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-03-22\",\"description\":\"Last cycle of TP chemotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"Adjuvant chemotherapy completed\",\"regimen_or_test\":\"TP\"},{\"date\":\"2022-04-18\",\"description\":\"Complete blood count showing thrombocytopenia\",\"event_type\":\"Lab\",\"key_result\":\"PLT:33\",\"regimen_or_test\":\"Blood routine\"},{\"date\":\"2022-04-26\",\"description\":\"Stopped niraparib due to strong adverse reactions\",\"event_type\":\"Other\",\"key_result\":\"Maintenance paused\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-05-23\",\"description\":\"Restarted niraparib 1# qd\",\"event_type\":\"Chemo\",\"key_result\":\"Maintenance resumed\",\"regimen_or_test\":\"尼拉帕利\"},{\"date\":\"2022-06-24\",\"description\":\"Abdominal wall hernia repair at Zhongshan Hospital\",\"event_type\":\"Surgery\",\"key_result\":\"Niraparib held for 3 weeks around surgery\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-09-27\",\"description\":\"CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior\",\"event_type\":\"Imaging\",\"key_result\":\"No new malignant findings reported; abdominal details deferred\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-08\",\"description\":\"CT showing liver segment VII hemangioma and left renal cyst, stable\",\"event_type\":\"Imaging\",\"key_result\":\"No new findings; chest to correlate with other exams\",\"regimen_or_test\":\"CT\"},{\"date\":\"2022-10-25\",\"description\":\"Pelvic MRI after ovarian cancer surgery\",\"event_type\":\"Imaging\",\"key_result\":\"No abnormal soft tissue in pelvis; follow-up recommended\",\"regimen_or_test\":\"MR\"},{\"date\":\"2022-12-30\",\"description\":\"Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe\",\"event_type\":\"Imaging\",\"key_result\":\"Blood count and liver/kidney function generally acceptable\",\"regimen_or_test\":\"Imaging\"},{\"date\":\"2023-01-09\",\"description\":\"Recent blood routine showed platelet count 34 (year not fully specified)\",\"event_type\":\"Lab\",\"key_result\":\"PLT:34 (interpreted from 'PLT:342022.5.23起恢复', year unclear)\",\"regimen_or_test\":\"Blood routine\"}]},\"TOXICITIES\":[{\"attribution\":\"Probable\",\"dose_modification\":\"Yes\",\"onset_date\":\"2022-04-18\",\"outcome\":\"Resolved\",\"related_line\":\"1L\",\"related_regimen\":\"尼拉帕利\",\"severity\":\"Severe\",\"toxicity\":\"Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)\"}]}\n\n# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)\n⚠️ COMPREHENSIVE NGS PANEL (~20,000 genes) - INTERPRETATION RULES:\n• '未检出' (not detected) = NO pathogenic mutation found\n• '（视为阴性）' (considered negative) = NO pathogenic mutation found\n• '阴性' (negative) = negative result\n• Genes with specific variants (e.g., 'NM_xxx:exon:c.xxx:p.xxx') = POSITIVE mutation\n• If a gene is NOT mentioned, it means NO pathogenic mutation (comprehensive panel)\n\n## Mutation Report 1 (ID: OH2201222, Date: 2022-01-24)\nHRD 阳性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）\n\n\nAVAILABLE TRIALS (compact; use id/name exactly as shown):\n[\n  {\n    \"id\": \"345\",\n    \"name\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2、3、4L\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、HER2 表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"王 涛\"\n    ],\n    \"phones\": [\n      \"18721569326\"\n    ],\n    \"_raw\": {\n      \"id\": \"345\",\n      \"项目名称\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2、3、4L\",\n      \"入组排除标准\": \"1、HER2 表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"王 涛\"\n      ],\n      \"联系电话\": [\n        \"18721569326\"\n      ]\n    }\n  },\n  {\n    \"id\": \"346\",\n    \"name\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"朱 俊\",\n    \"sponsor\": \"阿斯利康投资（中国）有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"江文燕\"\n    ],\n    \"phones\": [\n      \"15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"346\",\n      \"项目名称\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n      \"医生\": \"朱 俊\",\n      \"试验治疗/用药\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"阿斯利康投资（中国）有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"江文燕\"\n      ],\n      \"联系电话\": [\n        \"15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"348\",\n    \"name\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n    \"phase\": \"I期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n    \"sponsor\": \" 上海美雅珂生物技术有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n    \"key_inclusion\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"杨 珂\"\n    ],\n    \"phones\": [\n      \"17774582517\"\n    ],\n    \"_raw\": {\n      \"id\": \"348\",\n      \"项目名称\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n      \"医生\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n      \"试验治疗/用药\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n      \"期别\": \"I期\",\n      \"申请单位\": \" 上海美雅珂生物技术有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n      \"联系人\": [\n        \"杨 珂\"\n      ],\n      \"联系电话\": [\n        \"17774582517\"\n      ]\n    }\n  },\n  {\n    \"id\": \"350\",\n    \"name\": \"评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\",\n    \"phase\": \"Ⅰb/Ⅱ 期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"吴 勇、刘汝娇 、高水平\",\n    \"sponsor\": \"成都百利多特生物药业有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"单臂研究\\n\\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"李 想\"\n    ],\n    \"phones\": [\n      \"17703993082\"\n    ],\n    \"_raw\": {\n      \"id\": \"350\",\n      \"项目名称\": \"评价注射用BL-B01D1在复发或转移性妇科恶性肿瘤等多种实体瘤患者中的安全性、耐受性、药代动力学及有效性的Ib/II期临床研究\",\n      \"医生\": \"吴 勇、刘汝娇 、高水平\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\n注射用BL-B01D1（ADC，靶向靶向 EGFR 和 HER3 靶点，毒性分子：拓扑异构酶I 抑制剂）<br />\",\n      \"期别\": \"Ⅰb/Ⅱ 期\",\n      \"申请单位\": \"成都百利多特生物药业有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、经病理组织学和/或细胞学确诊的标准治疗失败或不耐受或目前尚无标准治疗的复发或转移性妇科恶性肿瘤\",\n      \"联系人\": [\n        \"李 想\"\n      ],\n      \"联系电话\": [\n        \"17703993082\"\n      ]\n    }\n  },\n  {\n    \"id\": \"351\",\n    \"name\": \" 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳、刘汝娇\",\n    \"sponsor\": \"西藏海思科制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）\",\n    \"key_inclusion\": \"既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"张倩野\"\n    ],\n    \"phones\": [\n      \"18627004197\"\n    ],\n    \"_raw\": {\n      \"id\": \"351\",\n      \"项目名称\": \" 一项评价HSK39775片单药用于晚期实体恶性肿瘤患者中的安全性、耐受性、PK/PD特征及初步有效性的Ⅰ/Ⅱ期临床研究\",\n      \"医生\": \"李佳佳、刘汝娇\",\n      \"试验治疗/用药\": \"HSK39775片（泛素特异性蛋白酶1抑制剂，USP1i）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"西藏海思科制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"既往接受过标准治疗或标准治疗不耐受或无标准治疗或无法获得标准治疗；\",\n      \"联系人\": [\n        \"张倩野\"\n      ],\n      \"联系电话\": [\n        \"18627004197\"\n      ]\n    }\n  },\n  {\n    \"id\": \"353\",\n    \"name\": \"在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"刘汝娇\",\n    \"sponsor\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n    \"lead_or_participation\": \"参与（天津市肿瘤医院 郝继辉）\",\n    \"treatment\": \"注射用西罗莫司（白蛋白结合型）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"刘 涵\"\n    ],\n    \"phones\": [\n      \"19109628595\"\n    ],\n    \"_raw\": {\n      \"id\": \"353\",\n      \"项目名称\": \"在晚期恶性实体瘤患者中评价注射用西罗莫司（白蛋白结合型）的安全性、耐受性、药代动力学特征以及初步疗效的I期临床研究\",\n      \"医生\": \"刘汝娇\",\n      \"试验治疗/用药\": \"注射用西罗莫司（白蛋白结合型）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n      \"牵头/参与\": \"参与（天津市肿瘤医院 郝继辉）\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者\",\n      \"联系人\": [\n        \"刘 涵\"\n      ],\n      \"联系电话\": [\n        \"19109628595\"\n      ]\n    }\n  },\n  {\n    \"id\": \"354\",\n    \"name\": \"一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"吴 勇\",\n    \"sponsor\": \" 浙江道尔生物科技有限公司\",\n    \"lead_or_participation\": \"参与（组长单位：上海市肺科医院）\",\n    \"treatment\": \"注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）\",\n    \"key_inclusion\": \"1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗\\n\\n2、HPV 16+\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"浦东/郭 伟 、徐汇/江文艳\"\n    ],\n    \"phones\": [\n      \"13156793722、15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"354\",\n      \"项目名称\": \"一项评价注射用DR30206治疗晚期实体瘤患者的安全性、耐受性和药代动力学特征的多中心、开放性I期临床研究\",\n      \"医生\": \"吴 勇\",\n      \"试验治疗/用药\": \"注射用DR30206（靶向 PD-L1、VEGF 和 TGFβ 的抗体融合蛋白）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 浙江道尔生物科技有限公司\",\n      \"牵头/参与\": \"参与（组长单位：上海市肺科医院）\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、充分标准治疗失败或不耐受标准治疗或无有效标准治疗<br />\\r\\n2、HPV 16+<br />\",\n      \"联系人\": [\n        \"浦东/郭 伟 、徐汇/江文艳\"\n      ],\n      \"联系电话\": [\n        \"13156793722、15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"358\",\n    \"name\": \"评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2-3线\",\n    \"biomarker\": null,\n    \"doctor\": \"张 剑 、李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"徐汇/牛紫嫣 浦东/刘雅琦\"\n    ],\n    \"phones\": [\n      \"15638299516 18636833967 \"\n    ],\n    \"_raw\": {\n      \"id\": \"358\",\n      \"项目名称\": \"评估JSKN033在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"张 剑 、李佳佳\",\n      \"试验治疗/用药\": \"JSKN033注射液（HER2 双特异性抗体偶联药物（ADC，毒性分子：拓扑异构酶I 抑制剂）与 PD-L1 抑制剂的高浓度皮下注射复方制剂）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2-3线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者\",\n      \"联系人\": [\n        \"徐汇/牛紫嫣 浦东/刘雅琦\"\n      ],\n      \"联系电话\": [\n        \"15638299516 18636833967 \"\n      ]\n    }\n  },\n  {\n    \"id\": \"359\",\n    \"name\": \"SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \">2L\",\n    \"biomarker\": null,\n    \"doctor\": \"张 剑 、李佳佳 、刘汝娇、 高水平\",\n    \"sponsor\": \"苏州盛迪亚生物医药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、组织学确诊的子宫颈癌；\\n\\n2、标准治疗失败或无标准治疗患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"黄洋洋\"\n    ],\n    \"phones\": [\n      \"13226861415\"\n    ],\n    \"_raw\": {\n      \"id\": \"359\",\n      \"项目名称\": \"SHR-4375注射液在晚期实体瘤患者中的安全性、耐受性、药代动力学及疗效的开放、单臂、多中心的I/II期临床研究\",\n      \"医生\": \"张 剑 、李佳佳 、刘汝娇、 高水平\",\n      \"试验治疗/用药\": \"SHR-4375（ADC ，靶向TF，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \"苏州盛迪亚生物医药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \">2L\",\n      \"入组排除标准\": \"1、组织学确诊的子宫颈癌；<br />\\r\\n2、标准治疗失败或无标准治疗患者<br />\",\n      \"联系人\": [\n        \"黄洋洋\"\n      ],\n      \"联系电话\": [\n        \"13226861415\"\n      ]\n    }\n  },\n  {\n    \"id\": \"361\",\n    \"name\": \"一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"Bayer Consumer Care AG\",\n    \"lead_or_participation\": \"参与\",\n    \"treatment\": \"单臂研究\\n\\nBAY 2927088（TKI，靶向HER2）\",\n    \"key_inclusion\": \"1、标准治疗失败或无标准治疗患者；\\n\\n2、HER2激活突变（本院或认证的机构）；\\n\\n3、需提供肿瘤组织切片。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"李金山\"\n    ],\n    \"phones\": [\n      \"18893190113 \"\n    ],\n    \"_raw\": {\n      \"id\": \"361\",\n      \"项目名称\": \"一项旨在携带HER2激活突变的转移性或不可切除实体瘤参与者中评价口服可逆性酪氨酸激酶抑制剂BAY 2927088的有效性和安全性的II期、开放性、篮式研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\nBAY 2927088（TKI，靶向HER2）<br />\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"Bayer Consumer Care AG\",\n      \"牵头/参与\": \"参与\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、标准治疗失败或无标准治疗患者；<br />\\r\\n2、HER2激活突变（本院或认证的机构）；<br />\\r\\n3、需提供肿瘤组织切片。<br />\",\n      \"联系人\": [\n        \"李金山\"\n      ],\n      \"联系电话\": [\n        \"18893190113 \"\n      ]\n    }\n  }\n]\n\nDECISION RULE (be conservative):\nRecommend ONE trial ONLY IF ALL are true:\n1) Cancer type / primary site clearly matches.\n2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).\n3) Required biomarker/subtype is explicitly present in case text (if trial requires it).\n4) No more than 2 critical eligibility confirmations remain.\n\nIf ANY of the above is not satisfied -> output None.\n\nOUTPUT TEMPLATE (EXACT; no extra text):\n\nTrial Recommendation:\n- id: <trial id or None>\n- name: <trial name or None>\n- Reason: <1 short sentence>\n- Missing eligibility confirmations (0-2 items):\n  - item1 (or \"None\")\n  - item2", "assistant_reply": "Trial Recommendation:\n- id: None\n- name: None\n- Reason: Disease setting/line and required biomarkers for available trials are not clearly met based on the case.\n- Missing eligibility confirmations (0-2 items):\n  - HER2 / TF / EGFR/HER3 / HPV16 status and other trial-specific biomarkers\n  - Clear documentation of recurrent/metastatic or unresectable disease and prior systemic therapy lines in the advanced setting", "timestamp": "2026-01-22T18:35:39.124580"}]}, "trace_events": [{"ts": "2026-01-22T18:33:43.234794", "event": "pipeline_start", "payload": {"visit_time": "2023-01-09 09:23:13.113000", "meta_info": "310103195705270044"}}, {"ts": "2026-01-22T18:33:43.235316", "event": "case_fingerprint", "payload": {"case_fingerprint": "fa2f34f1e565"}}, {"ts": "2026-01-22T18:33:43.722515", "event": "reports_loaded", "payload": {"lab_n": 152, "img_n": 24, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-10 09:23:13"}}, {"ts": "2026-01-22T18:33:48.417419", "event": "reports_selected", "payload": {"lab": {"chair": ["20230109|5600622|2023-01-09", "20230109|8300382|2023-01-09", "20230109|9701878|2023-01-09"], "oncologist": ["20230109|5600622|2023-01-09", "20230109|8300382|2023-01-09", "20230109|9701878|2023-01-09"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-09-27|CT|2022-09-27", "2022-09-29|CT|2022-09-29", "2022-10-25|MR|2022-10-25"], "oncologist": [], "radiologist": ["2022-09-27|CT|2022-09-27", "2022-09-29|CT|2022-09-29", "2022-10-25|MR|2022-10-25"], "pathologist": [], "nuclear": ["2022-09-27|CT|2022-09-27", "2022-09-29|CT|2022-09-29", "2022-10-25|MR|2022-10-25"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2201222|2022-01-24"], "oncologist": ["OH2201222|2022-01-24"], "radiologist": [], "pathologist": ["OH2201222|2022-01-24"], "nuclear": []}}}, {"ts": "2026-01-22T18:33:48.421527", "event": "rag_key_facts", "payload": {"facts": "DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2201222; date=2022-01-24; full_text=HRD 阳性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）"}}, {"ts": "2026-01-22T18:34:03.722822", "event": "rag_query", "payload": {"query": "High-grade serous ovarian carcinoma, platinum-sensitive, with peritoneal and nodal metastases (6/24 nodes); HRD-positive, BRCA1/2-negative on NGS; prior niraparib maintenance limited by severe thrombocytopenia but organ function otherwise acceptable; histology: High-grade serous carcinoma"}}, {"ts": "2026-01-22T18:34:03.722830", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-22T18:34:03.722831", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-22T18:34:03.722833", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-22T18:34:12.578670", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-22T18:34:12.578743", "event": "mdt_initial_opinion_role_start", "payload": {"role": "chair", "order": 1}}, {"ts": "2026-01-22T18:34:17.562141", "event": "mdt_initial_opinion_role_end", "payload": {"role": "chair", "chars": 552}}, {"ts": "2026-01-22T18:34:17.562196", "event": "mdt_initial_opinion_role_start", "payload": {"role": "oncologist", "order": 2}}, {"ts": "2026-01-22T18:34:19.914111", "event": "mdt_initial_opinion_role_end", "payload": {"role": "oncologist", "chars": 506}}, {"ts": "2026-01-22T18:34:19.914152", "event": "mdt_initial_opinion_role_start", "payload": {"role": "radiologist", "order": 3}}, {"ts": "2026-01-22T18:34:21.729447", "event": "mdt_initial_opinion_role_end", "payload": {"role": "radiologist", "chars": 483}}, {"ts": "2026-01-22T18:34:21.729499", "event": "mdt_initial_opinion_role_start", "payload": {"role": "pathologist", "order": 4}}, {"ts": "2026-01-22T18:34:23.840292", "event": "mdt_initial_opinion_role_end", "payload": {"role": "pathologist", "chars": 526}}, {"ts": "2026-01-22T18:34:23.840374", "event": "mdt_initial_opinion_role_start", "payload": {"role": "nuclear", "order": 5}}, {"ts": "2026-01-22T18:34:25.931538", "event": "mdt_initial_opinion_role_end", "payload": {"role": "nuclear", "chars": 513}}, {"ts": "2026-01-22T18:35:37.307415", "event": "mdt_discussion_end", "payload": {"merged_chars": 2302}}, {"ts": "2026-01-22T18:35:37.309263", "event": "trial_matching_start", "payload": {"trials_json_path": "files/all_trials_filtered.json"}}, {"ts": "2026-01-22T18:35:39.124618", "event": "trial_matching_end", "payload": {"recommended": false}}, {"ts": "2026-01-22T18:35:39.124630", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-22T18:35:45.226409", "event": "final_output_end", "payload": {"final_output_chars": 3300}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
